MISSION
Our mission is to develop novel technologies that will enable greater access of cell and gene therapies globally. We focus on R&D in next-generation point-of-care devices that will enable rapid, safe and affordable cell and gene therapies.
Current methods are:

Expensive
Labor and capital intensive
Labor and capital intensive

Produce cells that contain residual chemicals that have to be removed in post-processing and that increase the cost and time and reduce the quality of the cells.


Focus areas:
Stem cell (MSC) purification for autologous transplantation T-cell purification for CAR-T therapy Single-patient to industrial scale